Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lessons Learned From Treating 34 Million People With Hypertension: The Global HEARTS Initiative.

Journal of the American College of Cardiology·2025
Same author

Global Development Assistance for Health Allocated to Cardiovascular Disease Control, 2015 to 2022.

Journal of the American College of Cardiology·2025
Same author

CDC's Failure to Recommend COVID-19 Vaccination-"Shared Clinical Decision-Making" Is Abdication of Responsibility.

JAMA·2025
Same author

Dismantling Public Health Infrastructure, Endangering American Lives.

The New England journal of medicine·2025
Same author

Improved hypertension care requires measurement and management in health facilities, not mass screening.

Lancet (London, England)·2025
Same author

Fourth Time a Charm?-How to Make the UN High-Level Meeting on Noncommunicable Diseases Effective.

JAMA·2025

Related Experiment Video

Updated: Jul 10, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Controlling tuberculosis in India.

G R Khatri1, Thomas R Frieden

  • 1Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi.

The New England Journal of Medicine
|November 1, 2002
PubMed
Summary

India's tuberculosis control program, initiated in 1993, has significantly improved diagnosis and treatment success rates. This public health initiative has saved lives and provided substantial economic benefits, despite ongoing challenges.

Area of Science:

  • Public Health
  • Infectious Disease Control
  • Health Policy

Background:

  • Tuberculosis (TB) caused nearly 500,000 deaths annually in India.
  • Diagnosis and treatment for TB were historically inadequate, with less than half of patients receiving accurate diagnosis and effective treatment.

Purpose of the Study:

  • To analyze the impact of new policies implemented in 1993 on India's national tuberculosis control program.
  • To evaluate improvements in TB diagnosis, treatment, and patient outcomes.

Main Methods:

  • Analysis of data following the introduction of new policies in 1993.
  • Inclusion of increased resources, enhanced laboratory diagnostics, directly observed treatment, and standardized regimens.
  • Assessment of training for health workers and population access to services.

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jul 10, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Main Results:

  • Over 200,000 health workers trained; 436 million people gained access to services by 2001.
  • Approximately 3.4 million TB patients evaluated, with nearly 800,000 treated successfully (over 80% success rate).
  • Treatment rates increased significantly, with over half of all treated patients receiving care in the last year of the study period.

Conclusions:

  • India's TB control program demonstrated success in enhancing care access, diagnostic quality, and treatment outcomes.
  • The program is estimated to have prevented 200,000 deaths and generated over $400 million in indirect savings.
  • Sustaining and expanding the program faces challenges including economic development, healthcare system limitations, and the threats of HIV and multidrug-resistant TB.